Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trial.

导出 LinkOut

翻译打印收藏纠错

作者： Marcel de Paula,Pereira ^[1] ; Eduardo Gomes,Lima ^[1] ; Fabio Grunspun,Pitta ^[1] ; Luís Henrique Wolff,Gowdak ^[1] ; Bruno Mahler,Mioto ^[1] ; Leticia Neves Solon,Carvalho ^[1] ; Francisco Carlos da Costa,Darrieux ^[1] ; Omar Asdrubal Vilca,Mejia ^[1] ; Fabio Biscegli,Jatene ^[1] ; Carlos Vicente,Serrano ^[1]

作者单位： Instituto do coração, Hospital das clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil. ^[1]

关键词 anticoagulation coronary artery bypass surgery cost-effective costs direct oral anticoagulant postoperative atrial fibrillation

DOI 10.1016/j.xjon.2023.05.006

PMID 37808050

发布时间 2023-10-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

JTCVS open

2023年15卷

199-210页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trial.

JTCVS open

相似文献

JTCVS open

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trial.

JTCVS open

相似文献

JTCVS open

相关期刊

检索历史清除